{"filing":{"accession_number":"0001654954-26-009062","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"a7767z.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426009062/a7767z.htm"},"events":[{"id":36559,"run_id":33707,"accession_number":"0001654954-26-009062","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"GSK announced US FDA approval of Hibsago (bepirovirsen) for chronic hepatitis B treatment, a first-in-class antisense oligonucleotide achieving unprecedented 19% functional cure rates versus \u003c1% for standard care. This is a material regulatory milestone and product launch event that would affect investor assessment of GSK's pipeline, commercial prospects, and competitive position in hepatology, but does not fit the discrete event categories (not earnings, M\u0026A, litigation, or executive action). It is clearly operational/commercial rather than financial, governance, or legal in nature.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-10-21","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":41014,"accession_number":"0001654954-26-009062","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"GSK announced US FDA approval of Hibsago (bepirovirsen) for chronic hepatitis B treatment, a first-in-class antisense oligonucleotide achieving unprecedented 19% functional cure rates versus \u003c1% for standard care. This is a material regulatory milestone and product launch event that would affect investor assessment of GSK's pipeline, commercial prospects, and competitive position in hepatology, but does not fit the discrete event categories (not earnings, M\u0026A, litigation, or executive action). It is clearly operational/commercial rather than financial, governance, or legal in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T10:15:37.383340+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-10-21"}]}